Anna Puła, Paweł Robak and Tadeusz Robak* Pages 6753 - 6772 ( 20 )
Multiple myeloma (MM) is a common malignant hematological malignancy. Recently, interest has grown in the role of non-coding regions in disease pathogenesis. MicroRNAs (miRNAs) are small non-coding RNAs containing 19-25 bases that play a crucial role in messenger RNA silencing and post-transcriptional regulation of gene expression. Several miRNAs demonstrate markedly dysregulated expression in MM, suggesting that they may act as both tumor suppressors and oncogenes. microRNAs are also reportedly involved in the regulation of other epigenetic mechanisms of gene expression. Additionally, some miRNAs have been associated with drug resistance, and therefore a further exploration of their activity may lead to its reversal. Moreover, miRNA expression patterns in either MM cells or serum exosomes have been shown to be good prognostic markers. This review describes the roles of miRNAs in MM and examines their potential to predict MM prognosis and play a role in novel therapeutic strategies.
Bortezomib, drug resistance, epigenetics, microRNA, multiple myeloma, p53, pathogenesis, prognostic markers.
Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-510 Lodz Ul, Ciolkowskiego 2, Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-510 Lodz Ul, Ciolkowskiego 2, Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-510 Lodz Ul, Ciolkowskiego 2